Get the Stockscreener App
6.44
5.23%
0.32
After Hours:
6.48
0.04
+0.62%
Vir Biotechnology Inc stock is traded at $6.44, with a volume of 2.64M.
It is up +5.23% in the last 24 hours and up +7.69% over the past month.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
See More
Previous Close:
$6.12
Open:
$6.28
24h Volume:
2.64M
Relative Volume:
1.77
Market Cap:
$895.97M
Revenue:
$62.04M
Net Income/Loss:
$-533.34M
P/E Ratio:
-1.6429
EPS:
-3.92
Net Cash Flow:
$-473.07M
1W Performance:
+17.09%
1M Performance:
+7.69%
6M Performance:
+43.11%
1Y Performance:
-13.44%
1-Day Range:
$6.12
$6.61
1-Week Range:
$5.32
$6.61
52-Week Range:
$4.155
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
6.44 | 851.45M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Initiated | Evercore ISI | Outperform |
| Aug-27-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
H.C. Wainwright Keeps Their Buy Rating on Vir Biotechnology (VIR) - The Globe and Mail
How to manage a losing position in Vir Biotechnology Inc.Weekly Stock Report & AI Enhanced Trade Execution Alerts - newser.com
Is Vir Biotechnology Inc. stock gaining market shareRisk Management & Long Hold Capital Preservation Tips - newser.com
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference - BioSpace
How Vir Biotechnology Inc. stock reacts to job market dataWeekly Trade Analysis & Consistent Income Trade Ideas - newser.com
What margin trends mean for Vir Biotechnology Inc. stockMarket Trend Summary & Entry Point Confirmation Alerts - newser.com
Vir Biotechnology (NASDAQ:VIR) CFO Sells $37,802.44 in Stock - MarketBeat
Will Vir Biotechnology Inc. stock deliver consistent dividendsTrade Volume Summary & High Win Rate Trade Alerts - newser.com
Why Vir Biotechnology Inc. stock is favored by top institutionsJuly 2025 Momentum & Reliable Intraday Trade Alerts - newser.com
What to do if you’re stuck in Vir Biotechnology Inc.Market Trend Summary & Daily Stock Trend Reports - newser.com
How Vir Biotechnology Inc. stock reacts to oil pricesWeekly Volume Report & Target Return Focused Picks - newser.com
Vir Biotechnology EVP O’Byrne sells $37,782 in shares By Investing.com - Investing.com Nigeria
Vir Biotechnology EVP O’Byrne sells $37,782 in shares - Investing.com
[Form 4] Vir Biotechnology, Inc. Insider Trading Activity - Stock Titan
Vir Biotechnology EVP & CFO Jason O'Byrne Sells Shares - TradingView
CFO O'Byrne Surrenders 6,799 Of Vir Biotechnology Inc [VIR] - TradingView
Vir Biotechnology at Jefferies Conference: Advancing in Oncology and Infectious Diseases - Investing.com Canada
Risk adjusted return profile for Vir Biotechnology Inc. analyzedChart Signals & Verified Technical Signals - newser.com
Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown - MSN
CFO O'Byrne Files To Sell 6,799 Of Vir Biotechnology Inc [VIR] - TradingView
Is Vir Biotechnology Inc. forming a reversal patternPortfolio Update Report & Proven Capital Preservation Methods - newser.com
Is it too late to sell Vir Biotechnology Inc.2025 Trading Volume Trends & Daily Chart Pattern Signal Reports - newser.com
What analysts say about Vir Biotechnology Inc stockSupport Zone Identification & Rapid Portfolio Trading - earlytimes.in
Vir Biotechnology Inc. stock trendline breakdown2025 Earnings Impact & Reliable Trade Execution Plans - newser.com
Can technical indicators confirm Vir Biotechnology Inc.’s reversalRisk Management & Free Community Consensus Stock Picks - newser.com
Visualizing Vir Biotechnology Inc. stock with heatmapsJuly 2025 Closing Moves & Real-Time Buy Zone Alerts - newser.com
How to escape a deep drawdown in Vir Biotechnology Inc.Market Sentiment Review & Risk Controlled Daily Trade Plans - newser.com
What the charts say about Vir Biotechnology Inc. todayWeekly Profit Analysis & Community Verified Watchlist Alerts - newser.com
Best data tools to analyze Vir Biotechnology Inc. stock2025 Market Trends & Verified Trade Idea Suggestions - newser.com
Published on: 2025-11-13 12:49:36 - newser.com
Tools to monitor Vir Biotechnology Inc. recovery probabilityTrade Volume Report & Real-Time Buy Signal Alerts - newser.com
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):